Mensil N5 mg

Mensil N is a synthetic progestin used mainly in gynecological and hormonal therapy. Its indications are classified below by strength of evidence.

Established / approved uses

• Secondary amenorrhea — to induce withdrawal bleeding when pregnancy has been excluded and there is no organic pathology.
• Abnormal uterine bleeding due to hormonal imbalance, in the absence of organic pathology such as fibroids or malignancy.
• Endometriosis — for management of pelvic pain and disease-related symptoms.

Guideline-supported / combination uses

• As the progestin component of hormone replacement therapy (HRT), combined with estrogen, to protect the endometrium in women with an intact uterus.
• As the progestin component of certain combined hormonal contraceptives.

Other recognized use

• Menstrual delay — short-term postponement of menstruation for a defined period, when medically appropriate.

Mensil N is not an antibiotic and has no role in treating infections.

Each tablet contains Norethisterone Acetate INN as the active ingredient, commonly available as 5 mg tablets. Strength and pack size may vary by manufacturer and market; always check the product label of the dispensed brand.

Mensil N is a synthetic progestogen (a derivative of 19-nortestosterone) used in the management of various gynecological conditions related to hormonal imbalance. It is the acetate ester of norethisterone, which provides reliable oral bioavailability.

It works by mimicking the action of the natural hormone progesterone, producing secretory changes in the endometrium and, at higher doses, suppressing ovulation.

Mensil N belongs to the therapeutic class of Progestogens (synthetic progestins), a subgroup of sex hormones used in gynecology and hormone therapy.

Norethisterone Acetate is a synthetic progestin that binds to progesterone receptors in the endometrium, myometrium, hypothalamus, and pituitary gland.

• It converts a proliferative endometrium into a secretory one and, on withdrawal, produces organized shedding (withdrawal bleeding).
• At higher doses, it suppresses gonadotropin-releasing hormone (GnRH) pulsatility, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, which inhibits ovulation.
• It also thickens cervical mucus and induces endometrial atrophy with prolonged use, which is exploited in endometriosis and abnormal bleeding management.
• It has mild androgenic and anabolic activity due to its testosterone-derived structure.

After oral administration, Norethisterone Acetate is well absorbed and rapidly de-esterified to norethisterone, its active moiety, which is further metabolized in the liver and excreted mainly in urine.

Mensil N tablets are taken orally, generally with or without food, swallowed whole with a glass of water. For consistency, it is best taken at approximately the same time each day.

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose, in which case the missed dose should be skipped — do not double the dose. Do not stop or change the dose without consulting a physician.

Clinically significant interactions with Mensil N include:

• Hepatic enzyme inducers (e.g., rifampicin, carbamazepine, phenytoin, St. John's Wort) — may accelerate metabolism of Mensil N, reducing its effectiveness and increasing the risk of breakthrough bleeding or therapeutic failure.
• Lamotrigine — progestins can lower plasma lamotrigine levels, potentially reducing seizure control; dose adjustment of lamotrigine may be required.
• Ciclosporin — progestins may inhibit its metabolism, increasing ciclosporin levels and toxicity risk; monitoring is advised.
• Antidiabetic drugs — Mensil N may reduce glucose tolerance; dosage of insulin or oral hypoglycemics may need adjustment.
• Thyroid and corticosteroid-binding globulins — Mensil N can alter levels of binding proteins, which may affect interpretation of certain endocrine laboratory tests.

Side effects associated with Mensil N include:

Patients should seek prompt medical attention for severe leg pain/swelling, chest pain, sudden shortness of breath, sudden vision changes, or signs of jaundice.

Pregnancy: Mensil N is not indicated for use during pregnancy. It should not be used to diagnose pregnancy, and if pregnancy occurs or is suspected during treatment, Mensil N should be discontinued immediately and the patient should consult her physician, as some studies have raised concerns about fetal risk with progestin exposure in early pregnancy.

Lactation: Mensil N passes into breast milk in small amounts. Progestin-only agents are generally considered compatible with breastfeeding by many guidelines, but effects on milk quantity/quality cannot be excluded in some individuals. Mensil N should be used during breastfeeding only if clearly needed and the potential benefit justifies the potential risk to the infant; a physician should be consulted before use.

Use Mensil N with caution and under medical supervision in the following situations:

• Thromboembolic risk factors — obesity, smoking, immobilization, personal/family history of clotting disorders (see Contraindications for absolute exclusions).
• Cardiovascular risk factors — hypertension, existing heart disease; monitor closely.
• Fluid retention–sensitive conditions — epilepsy, migraine, cardiac or renal dysfunction, as Mensil N can cause fluid retention that may worsen these conditions.
• Diabetes mellitus — Mensil N may reduce glucose tolerance; monitor blood glucose.
• Mood disorders — Mensil N may cause or worsen depression; discontinue if severe depression develops.
• Hepatic impairment — use cautiously in mild impairment and avoid in active liver disease (see Contraindications).
• Breakthrough or irregular bleeding — investigate any unexplained or persistent abnormal bleeding during treatment.
• Visual disturbances — discontinue and evaluate promptly if sudden vision changes occur.

Reported effects of Mensil N overdose are generally mild and may include nausea, vomiting, breast tenderness, dizziness, abdominal discomfort, drowsiness, and withdrawal bleeding in females. There is no specific antidote.

In case of a suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic, provided under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment: Mensil N is contraindicated in active liver disease or significant hepatic impairment (see Contraindications); use with caution in mild impairment.

Renal impairment: No well-established dose adjustment is defined; use cautiously, particularly given the risk of fluid retention.

Elderly: Mensil N is not typically indicated in postmenopausal women except as a component of hormone replacement therapy; individualize therapy and monitor for cardiovascular and thromboembolic risk.

Pediatric patients: Not indicated before menarche; safety and efficacy in premenarchal girls have not been established.

Duration of Mensil N therapy depends on the indication: typically 5–10 days per cycle for secondary amenorrhea or abnormal uterine bleeding, and up to 6–9 months (sometimes longer under supervision) for endometriosis. The treating physician determines the exact duration and whether cyclical or continuous therapy is appropriate.

Progestins; sex hormones and modulators of the genital system

Norethisterone Acetate acts as an agonist at progesterone receptors in target tissues (endometrium, myometrium, hypothalamus, pituitary). This produces secretory transformation of the endometrium, thickens cervical mucus, and, at sufficient doses, suppresses the hypothalamic-pituitary-ovarian axis to inhibit ovulation. It also has weak androgenic and anabolic activity owing to its 19-nortestosterone backbone.

X

Safety and efficacy of Mensil N have not been established in pediatric or premenarchal patients. It is not indicated for use before the onset of menstruation, and use in adolescents should follow the same indications and precautions as in adults, under specialist gynecological supervision.